Clinical Trial Update: Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the combination of ipilimumab and nivolumab as adjuvant treatment for mucosal melanoma is listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosal Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Robert R. McWilliams, MD | Conditions: Mucosal Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING